期刊文献+

左西孟旦联合西地那非治疗慢性心力衰竭肺动脉高压的疗效观察 被引量:7

Efficacy of sildenafii combined with levosimendan on patients with chronic heart failure and pul-monary hypertension
原文传递
导出
摘要 目的观察左西孟旦联合西地那非治疗慢性心力衰竭合并肺动脉高压患者的疗效。方法收集2012年6月至2012年12月慢性充血性心力衰竭并肺动脉高压的住院患者30例,随机双盲将患者分为两组,治疗组15例,在常规治疗基础上使用西地那非和左西孟旦,左西孟旦注射液初始以12μg/kg,注射10min,随即以O.1μg/(kg·min),静脉点滴,持续时间24h,同时应用西地那非25mg,tid,连续服用30d,对照组给予常规治疗,如利尿剂、ACEI类、洋地黄类。用药前后化验NT—proBNP,应用美国通用公司的Vingrnedvivid7多功能彩色多普勒诊断仪测量左心室射血分数(LVEF)、肺动脉压。结果治疗组治疗前后LEVF提高(11.110±5.676)%,明显高于对照组[提高(2.700±1.977)%],差异有统计学意义(t=3.981,P0〈0.01),NT—proBNP下降(1844.730±858.340)pg/ml,显著高于对照组[下降(894.470±890.371)pg/ml],差异有统计学意义(t=3.064,P〈0.01),肺动脉压下降(8.400±3.869)mmHg,高于对照组[下降(3.600±3.291)mmHg],差异有统计学意义(t=3.660,P〈0.0I)。结论与常规治疗组相比,左西孟旦联合西地那非治疗老年慢性心力衰竭伴肺动脉压升高患者有效,能显著降低肺动脉压,降低NT—proBNP,改善心功能。 Objective To observe the efficacy of oral sildenafil combined with intravenous levo-simendan on patients with chronic heart failure and pulmonary hypertension. Methods From June 2012 to October 2012,18 patients with chronic congestive heart failure and pulmonary hypertension were ran-domised into control group and treatment group, with 15 cases in each group. In treatment group, on the basis of conventional treatment, patients were given an initial dose of levosimendan of 12 μg/kg, infused over 10 min,followed by a continuous infusion of 0. 1 p,g/( kg · min) for 24 h, and oral seldenafil of 75 mg/d for 30 days. The patients in control group were given conventional treatment. NT-proBNP were tested before and after drug therapy, and LVEF and pulmonary artery pressure were measured by Vingmed vivid 7 Multifunctional color Doppler diagnostic instrument. Results In treatment group, LVEF in-creased higher than that in control group [ ( 11.110 ± 5. 676) % vs (2. 700 ± 1. 977 ) % ], there was sig-nificant difference (t = 3.981 ,P 〈 0. 01 ); NT-proBNP decreased more in treatment group than that in control group [ ( 1844. 730 ± 858. 340 ) pg/ml vs (894. 470 ,± 890. 371 ) pg/ml ], there was significant difference( t = 3.064, P 〈 0. 01 ) ; pulmonary artery pressure in treatment group decreased more than that in control group [ (8.400 ± 11. 344)mm Hg vs (3. 600 ± 3.291 )mm Hg ], there was significant difference ( t = 3.660, P 〈 0. 01 ). Conclusions Compared with conventional treatment, leosimendan combined with sildenafil could significantly reduce the pulmonary artery pressure and the NT-proBNP in patients with chronic heart failure and pulmonary hypertension, improve cardiac function, so it is effective.
出处 《中国实用医刊》 2013年第19期14-16,共3页 Chinese Journal of Practical Medicine
关键词 左西孟旦 西地那非 慢性心力衰竭 肺动脉压升高 Levosimendan Sildenafll Chronic heart failure patients Pulmonary hypertension
  • 相关文献

参考文献12

  • 1刘晓方,刘振兵.慢性充血性心力衰竭的预后影响因素及干预[J].实用心脑肺血管病杂志,2006,14(2):166-168. 被引量:5
  • 2Dee GW. Acute decompensated heart failure :the shrinking role of in- otropic therapy[ Jl. J Am Coil Cardiol,2005,46( 1 ):65-67. 被引量:1
  • 3Cleland JG, Nilitin N, McGowan J. Levosimendan :first in a new class of inodilator for acute and chronic severe heart failure [ J ]. Expert REV cardiovasc Ther,2004,2 (1) :9-19. 被引量:1
  • 4Galii N, Manes A, Negro L, et al. A meta-analysis of randomized con- trolled trails in pulmonary arterial hypertension [ J ]. Eur Heart J, 2009,30 (4) : 394-403. 被引量:1
  • 5Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pul- monary hypertension[ J]. J Am Coil Cardio1,2004,43 (12 Suppl S) : S5-S12. 被引量:1
  • 6Malfatto G, Della Rosa F, Villani A, et al. Intermittent levosimendan infusions in advanced heart failure : favourable effects on ventricular function, neurohormonal balance, and one-year survival [ J]. J Cardio- vasc pharmacol,2012,60( 5 ) :450-455. 被引量:1
  • 7Giglioli C, Cecchi E, Landi D. Levosimendan produces an additional clinical and hemodynamic benefit in patients with decompensated heart failure successfully submitted to a fluid removal treatment [ J ]. Congest Heart Fail,2012,18 ( 1 ) :47-53. 被引量:1
  • 8Parissis JT,Adamopoulos S, Farmakis D, et al. Effects of serial levosi- mendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune action in patients with advanced heart failure[ J]. Heart,2006,92(12) :1768-1772. 被引量:1
  • 9Grossini E, Caimmi PP, Platini F, et al. Modulation of programmed forms of cell death by intracoronary levosimendan during regional myo- cardial i schemia anesthetized pigs [ J ]. Cardiovasc Drugs Ther, 2010, 24(1 ) :5-15. 被引量:1
  • 10Bogden S, Seferian A, Totoescu A, et al. Sldenafil reduces inflamma- tion and prevents pulmonary arterial remolding of the monocrotaline- induced disease in the wister rates [ J ]. Meadiea (Buehar) , 2012,7 (2) :109-116. 被引量:1

二级参考文献56

  • 1杨跃进,杨伟宪,胡奉环,尤士杰,王燕武,叶苓,陈纪林,高润霖,陈在嘉.冠状动脉血运重建术对左心室收缩功能严重减低患者左心室重构及收缩功能的作用[J].中国循环杂志,2004,19(5):328-331. 被引量:8
  • 2Simonneau G,Galiè N,Rubin LJ,et al.Clinical classification of pulmonary hypertension.J Am Coll Cardiol,2004,43:S5-S12. 被引量:1
  • 3Humbert M,Sitbon O,Simonneau G.Treatment of pulmonary arterial hypertension.N Engl J Med,2004,351:1425-1436. 被引量:1
  • 4Kuhn KP,Byme DW,Arbogast PG,et al.Outcome in 91consecutive patients patients with pulmonary arterial hypertension receiving epoprostenol.Am J Respir Crit Care Med,2003,167:580-586. 被引量:1
  • 5Rubin LJ,Badesch DB,Barst RJ,et al.Bosentan therapy for pulmonary arterial hypertension.N Engl J Med,2002,346:896-903. 被引量:1
  • 6Kataoka M,Satoh T,Manabe T,et al.Oral sildenafil improves primary pulmonary hypertension refractory to epoprostenol.Circ J,2005,69:461-465. 被引量:1
  • 7Sastry BK,Narasimhan C,Reddy NK,et al.Clinical efficacy of sildenafil in primary pulmonary hypertension:a randomized,placebo-controlled,double-blind,crossover study.J Am Coll Cardiol,2004,43:1149-1153. 被引量:1
  • 8Galiè N,Ghofrani HA,Torbicki A,et al.Sildenafil citrate therapy for pulmonary arterial hypertension.N Engl J Med,2005,353:2148-2157. 被引量:1
  • 9Garg N,Sharma MK,Sinha N.Role of oral sildenafil in severe pulmonary arterial hypertension:clinical efficacy and dose response relationship.Int J Cardiol,2007,120:306-313. 被引量:1
  • 10Karatza AA,Bush A,Magee AG.Safety and efficacy of Sildenafil therapy in children with pulmonary hypertension.Int J Cardiol,2005,100:267-273. 被引量:1

共引文献23

同被引文献82

  • 1闫素琴.单硝酸异山梨酯与低分子肝素治疗肺心病心力衰竭60例临床分析[J].河北北方学院学报(医学版),2007,24(3):64-65. 被引量:6
  • 2Ning Yin,Stephanie Kaestle,Jun Yin,Thomas Hentschel,Axel R. Pries,Hermann Kuppe,Wolfgang M. Kuebler.Inhaled nitric oxide versus aerosolized iloprost for the treatment of pulmonary hypertension with left heart disease[J]. Critical Care Medicine . 2009 (3) 被引量:2
  • 3Maya Guglin,Hammad Khan.Pulmonary Hypertension in Heart Failure[J]. Journal of Cardiac Failure . 2010 (6) 被引量:2
  • 4Carolyn S.P. Lam,Véronique L. Roger,Richard J. Rodeheffer,Barry A. Borlaug,Felicity T. Enders,Margaret M. Redfield.Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction[J]. Journal of the American College of Cardiology . 2009 (13) 被引量:1
  • 5Robert M. Califf,Kirkwood F. Adams,William J. McKenna,Mihai Gheorghiade,Barry F. Uretsky,Steven E. McNulty,Harald Darius,Kevin Schulman,Faiez Zannad,Eileen Handberg-Thurmond,Frank E. Harrell,William Wheeler,Jordi Soler-Soler,Karl Swedberg.??A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST)(J)American Heart Journal . 1997 (1) 被引量:1
  • 6Carla A. Sueta,Mihai Gheorghiade,Kirkwood F. Adams,Robert C. Bourge,Srinivas Murali,Barry F. Uretsky,Marc R. Pritzker,Michael D. McGoon,Samuel M. Butman,Steven H. Grossman,James W. Crow,Christy L. Shaffer,Michael D. Thorn.??Safety and efficacy of epoprostenol in patients with severe congestive heart failure(J)The American Journal of Cardiology . 1995 (3) 被引量:1
  • 7Neal A. Chatterjee,Gregory D. Lewis.What Is the Prognostic Significance of Pulmonary Hypertension in Heart Failure?. CIRCULATION-HEART FAILURE . 2011 被引量:1
  • 8Houssaini, Amal,Abid, Shariq,Mouraret, Nathalie,Wan, Feng,Rideau, Dominique,Saker, Mirna,Marcos, Elisabeth,Tissot, Claire-Marie,Dubois-Rand?, Jean-Luc,Amsellem, Val?rie,Adnot, Serge.??Rapamycin Reverses Pulmonary Artery Smooth Muscle Cell Proliferation in Pulmonary Hypertension(J)American Journal of Respiratory Cell and Molecular Biology . 2013 (5) 被引量:1
  • 9Francesca Bursi,Sheila M. McNallan,Margaret M. Redfield,Vuyisile T. Nkomo,Carolyn S.P. Lam,Susan A. Weston,Ruoxiang Jiang,Véronique L. Roger.??Pulmonary Pressures and Death in Heart Failure(J)Journal of the American College of Cardiology . 2012 (3) 被引量:1
  • 10Amit Varma,Keyur B. Shah,Michael L. Hess.??Phosphodiesterase Inhibitors, Congestive Heart Failure, and Sudden Death: Time for Re‐Evaluation(J)Congestive Heart Failure . 2012 (4) 被引量:1

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部